China Biologic Products (CBPO) Earning Somewhat Positive News Coverage, Study Finds
Media coverage about China Biologic Products (NASDAQ:CBPO) has trended somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. China Biologic Products earned a news impact score of 0.19 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 46.4576931388661 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news articles that may have effected Accern’s scoring:
- Chartists Placing China Biologic Products Inc (CBPO) on Their Radar – Financial News Review (finnewsreview.com)
- Future outlook on Conjugated Drug Market with deep study on Influencing Factors with pin-point analysis to increase market rapidly (medgadget.com)
- Are Cagey Traders Interested in Esterline Technologies Corporation (NYSE:ESL) or China Biologic Products Holdings … – FLBC News (flbcnews.com)
- China Biologic Products Inc (CBPO) Sees AroonUp Sit Above Key Level – Sparta Review (spartareview.com)
- Stock Monitor: Looking at the Levels on Shares of China Biologic Products Holdings, Inc. (NASDAQ:CBPO) – Sparta Review (spartareview.com)
China Biologic Products (CBPO) opened at 89.95 on Wednesday. The company has a 50-day moving average price of $97.37 and a 200 day moving average price of $105.85. The firm has a market cap of $2.45 billion, a PE ratio of 23.41 and a beta of 1.70. China Biologic Products has a 12 month low of $88.25 and a 12 month high of $126.47.
China Biologic Products (NASDAQ:CBPO) last released its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $1.35 EPS for the quarter, beating the Zacks’ consensus estimate of $1.30 by $0.05. The firm had revenue of $89.28 million for the quarter, compared to analyst estimates of $97.33 million. China Biologic Products had a net margin of 31.55% and a return on equity of 21.86%. The company’s revenue for the quarter was down 2.3% compared to the same quarter last year. During the same period in the previous year, the business earned $1.26 earnings per share. Equities research analysts anticipate that China Biologic Products will post $4.96 EPS for the current year.
CBPO has been the topic of several recent research reports. Zacks Investment Research cut China Biologic Products from a “hold” rating to a “sell” rating in a research report on Friday, May 5th. Jefferies Group LLC restated a “buy” rating and issued a $140.00 price target on shares of China Biologic Products in a research report on Monday, June 12th. BidaskClub cut China Biologic Products from a “hold” rating to a “sell” rating in a research report on Sunday, July 16th. Finally, Goldman Sachs Group, Inc. (The) initiated coverage on China Biologic Products in a research report on Tuesday, May 30th. They issued a “neutral” rating on the stock. Two analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company. China Biologic Products has a consensus rating of “Hold” and an average target price of $132.00.
China Biologic Products Company Profile
Receive News & Stock Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related stocks with our FREE daily email newsletter.